NetworkNewsBreaks – Co-Diagnostics, Inc. (NASDAQ: CODX) Announces Continued Increase of COVID-19 Test Orders in the US

April 21, 2020 10:45:31

Co-Diagnostics (NASDAQ: CODX), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, on Monday announced continued increase of its COVID-19 test sales in the United States as the federal government shifts responsibility to individual states to confront the need to double the amount of testing for the disease. Per the update, the Company received FDA Emergency Use Authorization on April 3, 2020, and has shipped tests to more than a dozen states throughout the country, in addition to receiving orders from nearly 50 countries worldwide. “It has been widely reported that the most important step to returning to normal economic and social activity is a dramatic increase in the scale of testing being performed, and governors across the country are anxious to obtain more tests,” Co-Diagnostics CEO Dwight Egan said in the news release. “Sales of our Logix Smart(TM) COVID-19 test continue to be made to more and more states, countries, and labs. Through some 50 distributors and direct sales, our tests are being sold to individual labs, through government tenders, and to private/public partnerships designed to facilitate high throughput testing and increase test availability to the public. The Company’s high quality, cost-efficient, easy to interpret tests are in high demand around the world.”

To request access to the full report, visit http://nnw.fm/TTP6r

About Co-Diagnostics, Inc.:

Co-Diagnostics, Inc., a Utah corporation, is a molecular diagnostics company that develops, manufactures and markets a new, state-of-the-art diagnostics technology. The Company’s technology is utilized for tests that are designed using the detection and/or analysis of nucleic acid molecules (DNA or RNA). The Company also uses its proprietary technology to design specific tests to locate genetic markers for use in industries other than infectious disease and license the use of those tests to specific customers. For more information, visit www.CoDiagnostics.com.

About NetworkNewsWire

NetworkNewsWire (NNW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) NetworkNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, NNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. NNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, NNW brings its clients unparalleled visibility, recognition and brand awareness. NNW is where news, content and information converge.

To receive SMS text alerts from NetworkNewsWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information please visit https://www.NetworkNewsWire.com

Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer

NetworkNewsWire (NNW)
New York, New York
www.NetworkNewsWire.com
212.418.1217 Office
Editor@NetworkNewsWire.com

NetworkNewsWire is part of the InvestorBrandNetwork.